Scancell's Chief Executive Officer, Lindy Durrant, recently sat down with Sarah Lowther from focusIR. During the interview Lindy highlights Scancell’s innovative cancer vaccines, SCIB1 and Modi-1, providing a recap of the impressive clinical data seen thus far. She also discusses the Company’s strategy to do deals with major pharmaceutical companies and explores how revenues from Scancell’s pre-clinical antibody platform help mitigate risk by providing non-dilutive cash to drive the Company's other assets forward in development.

Watch the Interview with Professor Lindy Durrant and focusIR 

To download click here

For further information click here

CEO Cliff Holloway tells Proactive London why its antibody collaboration deal is significant and details how it complements Scancell's existing antibody technology. He also explains what is unique about Scancell's antibody pipeline.

The company is teaming up with an unnamed "major player" in the world of antibodies.

[View Article]

A £3.9mln injection from the life sciences fund Vulpes will effectively bankroll the latest R&D.

[View article]

Discussions with US regulators have taken longer than expected, so Scancell will now focus its efforts on completing the UK arm of the trial before re-submitting its US application at a later date.

[View article]

[View interview]